Common COVID-19 medications associated with small reduced risk of lingering symptoms

Embargoed until: Publicly released: 2023-10-24 02:00

International

Photo by Alex Boyd on Unsplash

Common COVID-19 medications nirmatrelvir (Paxlovid) and molnupiravir are associated with a small reduced risk of lingering symptoms from infection in older people, according to international researchers. The researchers looked at post-COVID-19 conditions - COVID-19 symptoms persisting between one and three months after infection - among nearly 2 million people aged 65 and over in the US. 19.5% of the cohort were treated with nirmatrelvir while 2.6% received molnupiravir. The researchers say the rate of lingering COVID-19 systems was 11.8% in the nirmatrelvir group, 13.7% in the molnupiravir group and 14.5% for those who did not receive either treatment.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Internal Medicine

Research:Paper

Organisation/s: National Library of Medicine, USA

Funder: This research was supported by the Intramural Research Program of the NIH, National Library of Medicine.

Media Contact/s

Contact details are only visible to registered journalists.